This can be used to target cancers with overexpression of oncogenes, for example, mitotic arrest deficiency 2 (MAD2) and protein-coding phosphatase 2 (PP2A), cyclin-dependent kinase regulatory subunit 1B (CKS1B) and Polo-like kinase 1 (PLK1), KRAS and CDKN1A (p21). This evidence concerns the gene KRAS and cancer.